Financial Results, Major Initiatives, New Technologies, and Leadership Appointments - Analyst Notes on Steris, Volcano, Masimo, Spectranetics and Orthofix

NEW YORK, May 15, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Steris Corp. (NYSE: STE), Volcano Corporation (NASDAQ: VOLC), Masimo Corporation (NASDAQ: MASI), The Spectranetics Corporation (NASDAQ: SPNC) and Orthofix International N.V. (NASDAQ: OFIX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2480-100free.

--
Steris Corp. Analyst Notes
On May 8, 2014, Steris Corp. (Steris) reported its Q4 FY 2014 and full-year FY 2014 financial results (period ended March 31, 2014). The Company reported revenue of $465.3 million compared to $428.2 million in Q4 FY 2013. Quarterly net income totaled $38.9 million, or $0.65 per diluted share, compared with net income of $41.4 million, or $0.70 per diluted share, in Q4 FY 2013. Full-year FY 2014 revenue grew 8% YoY to $1.6 billion, while net income totaled $129.4 million or $2.17 per diluted share, compared to $160.0 million, or $2.72 per diluted share in full-year FY 2013. "We are pleased to report another record year," said Walt Rosebrough, President and CEO of Steris. "On an adjusted basis, we grew the top-line 10% and operating income 14% in fiscal 2014. We anticipate another record year of revenue and adjusted earnings for fiscal 2015, and are excited about the way our people are performing and the platforms we are building to realize our long-term objectives." The Company expects revenue growth in the range of 15% to 17% YoY in FY 2015 and adjusted earnings per diluted share to be in the range of $2.78 to $2.91. The full analyst notes on Steris are available to download free of charge at:

http://www.analystsreview.com/2480-STE-15May2014.pdf

--
Volcano Corporation Analyst Notes
On May 2, 2014, Volcano Corporation (Volcano) reported its Q1 2014 financial results with reported revenues of $94.5 million compared to $93.2 million in Q1 2013. The Company reported a net loss of $10.9 million, or $0.21 per share during the quarter, compared to a net loss of $3.2 million, or $0.06 per share in Q1 2013. "Volcano is off to a good start in 2014 with growth of our core businesses, the roll out of new products and an expanded and realigned sales force that we believe will drive growth acceleration through the remainder of 2014 and into 2015," said Scott Huennekens, President and CEO of Volcano. The Company reaffirmed its outlook for full-year 2014 and expects revenues on a reported basis in the range of $413.0 million to $421.0 million. The full analyst notes on Volcano are available to download free of charge at:

http://www.analystsreview.com/2480-VOLC-15May2014.pdf

--
Masimo Corporation Analyst Notes
On May 2, 2014, Masimo Corporation (Masimo) announced that it will celebrate its Silver 25th Anniversary with major initiatives to improve patient safety. The celebration will start on June 5, 2014 with a worldwide Day of Volunteering in the name of eliminating preventable patient deaths. Teams of Masimo volunteers from across the globe will call on the world's acute-care hospitals to make public commitments to patient safety and report the measurable steps they have taken or will take to eliminate preventable patient deaths, aiding the Patient Safety Movement Foundation's goal of zero preventable deaths by 2020. Also as part of its 25th anniversary, Masimo has announced a donation of $2.5 million to the Masimo Foundation for Ethics, Innovation and Competition in Healthcare. Masimo also said that it will unveil at least one new clinically significant product a month for the remainder of this year in an engineering push to accelerate innovative technologies that improve patient outcomes and safety, while reducing the cost of care. The full analyst notes on Masimo are available to download free of charge at:

http://www.analystsreview.com/2480-MASI-15May2014.pdf

--
The Spectranetics Corporation Analyst Notes
On May 7, 2014, The Spectranetics Corporation (Spectranetics) announced that it has successfully completed the first live case using the TightRail™ Rotating Dilator Sheath performed by Charles Love, MD. "I was very pleased with how TightRail handled and tracked through the vasculature," said Dr. Love. "It easily passed through occlusions in the chronically occluded innominate vein and superior vena cava. These included areas that had some calcification. We easily and safely achieved the clinical goal. TightRail had no effect on the non-targeted leads in our experience." The Company said that the procedure represents a significant milestone as the company readies the TightRail tool for full launch later this month. The full analyst notes on Spectranetics are available to download free of charge at:

http://www.analystsreview.com/2480-SPNC-15May2014.pdf

--
Orthofix International N.V. Analyst Notes
On May 5, 2014, Orthofix International N.V. (Orthofix) announced that Mark A. Heggestad has been appointed as the Company's CFO. He succeeds David Ziegler, who has been serving as Interim CFO and will now assist Mr. Heggestad in his transition and continue to provide consulting services to the Company. "We are excited to welcome Mark to the Orthofix team," said Orthofix President and CEO Brad Mason. "There is a lot to do in the next few years to become best in class in our finance and business processes. I believe Mark will be a great partner to the executive team and me in leading these efforts and that he will keep the company focused on the key initiatives that will drive shareholder value." The full analyst notes on Orthofix are available to download free of charge at:

http://www.analystsreview.com/2480-OFIX-15May2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review